367 related articles for article (PubMed ID: 27785071)
1. Current classification, treatment options, and new perspectives in the management of adipocytic sarcomas.
De Vita A; Mercatali L; Recine F; Pieri F; Riva N; Bongiovanni A; Liverani C; Spadazzi C; Miserocchi G; Amadori D; Ibrahim T
Onco Targets Ther; 2016; 9():6233-6246. PubMed ID: 27785071
[TBL] [Abstract][Full Text] [Related]
2. Established and Experimental Systemic Treatment Options for Advanced Liposarcoma.
Schöffski P
Oncol Res Treat; 2022; 45(9):525-543. PubMed ID: 35609512
[TBL] [Abstract][Full Text] [Related]
3. A contemporary review of myxoid adipocytic tumors.
Creytens D
Semin Diagn Pathol; 2019 Mar; 36(2):129-141. PubMed ID: 30853315
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in the understanding and management of liposarcoma.
Haddox CL; Riedel RF
Fac Rev; 2021; 10():1. PubMed ID: 33659920
[TBL] [Abstract][Full Text] [Related]
5. Liposarcoma: new entities and evolving concepts.
Dei Tos AP
Ann Diagn Pathol; 2000 Aug; 4(4):252-66. PubMed ID: 10982304
[TBL] [Abstract][Full Text] [Related]
6. [Histology-Specific Chemotherapy in Soft-Tissue Sarcomas].
Kobayashi E; Kawai A
Gan To Kagaku Ryoho; 2017 Jun; 44(6):468-472. PubMed ID: 28698435
[TBL] [Abstract][Full Text] [Related]
7. Application of molecular biology to individualize therapy for patients with liposarcoma.
Abbas Manji G; Singer S; Koff A; Schwartz GK
Am Soc Clin Oncol Educ Book; 2015; ():213-8. PubMed ID: 25993159
[TBL] [Abstract][Full Text] [Related]
8. Managing Liposarcomas: Cutting Through the Fat.
Manji GA; Schwartz GK
J Oncol Pract; 2016 Mar; 12(3):221-7. PubMed ID: 26962163
[TBL] [Abstract][Full Text] [Related]
9. A large well-differentiated spindle cell liposarcoma (atypical spindle cell lipomatous tumor): clinicopathologic and immunohistochemical analysis. Diagnostic and therapeutic features.
Pironi D; Vendettuoli M; Tesori C; Salvati B; Pontone S; Pietraforte E; Filippini A
Ann Ital Chir; 2014 Dec; 85(ePub):. PubMed ID: 25624426
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy for liposarcoma: current state of the art and emerging systemic treatments.
Suarez-Kelly LP; Baldi GG; Gronchi A
Expert Opin Pharmacother; 2019 Aug; 20(12):1503-1515. PubMed ID: 31136210
[No Abstract] [Full Text] [Related]
11. Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection.
Lesovaya EA; Fetisov TI; Bokhyan BY; Maksimova VP; Kulikov EP; Belitsky GA; Kirsanov KI; Yakubovskaya MG
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254762
[TBL] [Abstract][Full Text] [Related]
12. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
[TBL] [Abstract][Full Text] [Related]
13. Pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.
Chamberlain FE; Wilding C; Jones RL; Huang P
Expert Opin Investig Drugs; 2019 Jun; 28(6):505-511. PubMed ID: 31010343
[No Abstract] [Full Text] [Related]
14. Soft tissue liposarcoma: histological subtypes, MRI and CT findings.
Barile A; Zugaro L; Catalucci A; Caulo M; Di Cesare E; Splendiani A; Gallucci M; Masciocchi C
Radiol Med; 2002 Sep; 104(3):140-9. PubMed ID: 12471362
[TBL] [Abstract][Full Text] [Related]
15. Liposarcomas: diagnostic pitfalls and new insights.
Dei Tos AP
Histopathology; 2014 Jan; 64(1):38-52. PubMed ID: 24118009
[TBL] [Abstract][Full Text] [Related]
16. Fibrosarcoma-like lipomatous neoplasm: a reappraisal of so-called spindle cell liposarcoma defining a unique lipomatous tumor unrelated to other liposarcomas.
Deyrup AT; Chibon F; Guillou L; Lagarde P; Coindre JM; Weiss SW
Am J Surg Pathol; 2013 Sep; 37(9):1373-8. PubMed ID: 23887155
[TBL] [Abstract][Full Text] [Related]
17. Oncogene mutation profiling reveals poor prognosis associated with FGFR1/3 mutation in liposarcoma.
Li C; Shen Y; Ren Y; Liu W; Li M; Liang W; Liu C; Li F
Hum Pathol; 2016 Sep; 55():143-50. PubMed ID: 27237367
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors.
Thway K; Flora R; Shah C; Olmos D; Fisher C
Am J Surg Pathol; 2012 Mar; 36(3):462-9. PubMed ID: 22301498
[TBL] [Abstract][Full Text] [Related]
19. Atypical lipomatous tumor/well-differentiated liposarcoma: what is it?
Hogg ME; Wayne JD
Surg Oncol Clin N Am; 2012 Apr; 21(2):333-40. PubMed ID: 22365523
[TBL] [Abstract][Full Text] [Related]
20. Subclassification of pleomorphic sarcomas: How and why should we care?
Hornick JL
Ann Diagn Pathol; 2018 Dec; 37():118-124. PubMed ID: 30340082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
